RMC No. 19-2023 confirms FDA-endorsed VAT-exempt medicine and medical device updates, with CREATE Act exemption effective from FDA publication date.
Businesses selling, purchasing, importing, prescribing, distributing, or accounting for VAT-exempt medicines and medical devices must verify whether their products are included in the Food and Drug Administration’s updated VAT-exempt list, because VAT exemption under the CREATE Act becomes effective only from the date the FDA publishes the applicable update. RMC No. 19-2023 matters now for hospitals, pharmacies, drugstores, importers, distributors, manufacturers, health maintenance organizations, accountants, and VAT-registered businesses that need to determine whether a sale should be treated as VAT-exempt or subject to the 12% value-added tax.
What RMC No. 19-2023 Changed
RMC No. 19-2023 publishes the full text of the January 4, 2023 letter from the Food and Drug Administration of the Department of Health endorsing updates to the list of VAT-exempt products under Republic Act No. 10963, known as the TRAIN Law, and Republic Act No. 11534, known as the CREATE Act. The practical effect is that the BIR is giving official tax notice that the FDA has endorsed an updated list of covered medicines and medical devices for VAT-exempt treatment.
The key rule is not merely that a medicine or device is health-related. The product must be within the FDA-published update to the list of VAT-exempt medicines or medical devices. For tax teams, this means the product’s VAT treatment should be supported by a match to the relevant FDA list, product description, and applicable statutory category. A taxpayer should not assume that all medicines, all medical supplies, or all COVID-19-related goods are VAT-exempt simply because they are used in healthcare.
The issuance specifically refers to certain medicines and medical devices for COVID-19 treatment, and to the list of VAT-exempt medicines under the CREATE Act. It also connects the update to the statutory VAT-exemption framework under the TRAIN Law and CREATE Act. In business terms, RMC No. 19-2023 is relevant to searches and compliance reviews involving VAT-exempt medicines Philippines, FDA list of VAT-exempt medicines, CREATE Act VAT exemption on medicines, TRAIN Law VAT-exempt drugs, COVID-19 treatment VAT exemption, and BIR VAT-exempt medical devices.
Who Is Affected by the VAT-Exempt Product Update
The most directly affected businesses are pharmacies, hospital pharmacies, private hospitals, clinics, pharmaceutical manufacturers, drug importers, medical device importers, wholesalers, retailers, distributors, and businesses that sell FDA-regulated medicines or medical devices. The ruling also affects VAT-registered suppliers that issue invoices for covered products, because they must determine whether to charge 12% VAT or treat the sale as VAT-exempt.
Corporate accountants, CFOs, tax managers, and in-house counsel should review this issuance if their company buys or sells medicines, medical devices, or healthcare products. Even businesses outside the healthcare sector may be affected if they purchase covered medicines or devices for employee health programs, clinics, welfare programs, or occupational health requirements. For sellers, the main risk is incorrect VAT treatment at the point of sale. For buyers, the main risk is relying on an invoice that improperly treats an item as VAT-exempt or VATable.
The issuance is also important for withholding agents and large taxpayers that maintain strict procurement, accounting, and tax documentation controls. If VAT is not charged because the item is treated as VAT-exempt, the business should be able to show why the exemption applies. If VAT is charged on a product that is actually VAT-exempt under the FDA-published list, the buyer and seller may need to review whether invoicing, pricing, and accounting entries should be corrected.
Effective Date and Compliance Timing
The most important timing rule in RMC No. 19-2023 is that, as clarified in Q&A No. 1 of RMC No. 99-2021, the effectivity of the VAT exemption of covered medicines and medical devices under the CREATE Act is the date of publication by the FDA of the update to the list. This is the date taxpayers should examine when deciding when VAT-exempt treatment begins for a specific product included in the update.
RMC No. 19-2023 itself is dated February 6, 2023, while the FDA letter it publishes is dated January 4, 2023. For tax compliance, the decisive issue is not simply the date of the BIR issuance. Taxpayers must identify the date when the FDA published the relevant update to the list, because the CREATE Act VAT exemption for the covered medicine or medical device takes effect from that FDA publication date.
This timing rule matters for cut-off testing. A pharmacy, hospital, importer, or distributor may have sales before and after the FDA publication date. Sales before the effective date may not automatically enjoy VAT-exempt treatment under the update, while sales from the effective date may be treated as VAT-exempt if the product is covered. Accounting teams should therefore review sales invoices, official receipts, billing systems, enterprise resource planning product tax codes, and inventory master files based on the proper effective date.
Key Compliance Requirements for Businesses
First, businesses should confirm whether each product is included in the FDA-published update. This should be done at the SKU, brand, generic name, product registration, or product description level, depending on how the FDA list identifies the medicine or device. A general category match is not enough if the list is product-specific.
Second, sellers should update their invoicing systems so that covered products are tagged as VAT-exempt only from the proper effective date. If a product was previously subject to 12% VAT but is now included in the updated list, the change should be reflected in the point-of-sale system, accounting system, billing templates, and tax reporting workpapers. Businesses should avoid applying the exemption retroactively without support from the FDA publication date rule.
Third, importers and distributors should coordinate among regulatory, finance, and tax teams. The FDA endorsement is a regulatory event with direct tax consequences. The tax department should not wait until the monthly or quarterly VAT return preparation stage to discover that a product’s VAT classification has changed. Companies should maintain a file showing the product’s inclusion in the FDA update, the effective date relied upon, and the internal approval for changing the VAT code.
Fourth, buyers should review invoices for high-value purchases of medicines and medical devices. Where the supplier treats the product as VAT-exempt, the buyer should confirm that the product appears in the relevant FDA-published list. Where the supplier charges 12% VAT despite possible inclusion in the list, the buyer may need to request clarification or correction. This is especially important for hospitals, clinics, and institutional buyers that purchase large volumes of regulated healthcare products.
Penalties and Risk of Non-Compliance
RMC No. 19-2023 does not create a special penalty schedule for non-compliance. However, incorrect VAT treatment can still create ordinary tax exposure under the National Internal Revenue Code and BIR audit rules. A seller that fails to impose VAT on a product not properly covered by the exemption may face deficiency VAT, surcharge, interest, and compromise penalties. A seller that charges VAT on a product that should be VAT-exempt may face customer disputes, invoice correction issues, and possible tax reporting complications.
The bigger practical risk is audit defensibility. BIR examiners may ask why a product was treated as VAT-exempt, when the exemption took effect, and what document supports the exemption. A taxpayer that cannot produce the FDA list, the relevant update, and the effective date analysis may have difficulty defending the VAT treatment during audit, refund review, or reconciliation of VAT sales.
Practical Steps for CFOs, Accountants, and Healthcare Businesses
Businesses should immediately create or update a VAT-exempt medicine and medical device matrix. The matrix should identify the product, supplier, regulatory basis, FDA publication date, BIR issuance reference, VAT treatment, system tax code, and responsible approving officer. This is a practical control for companies handling thousands of healthcare SKUs.
Finance teams should also reconcile sales reports against VAT returns for periods affected by the FDA update. If the product tax code was changed late, there may be invoices that were issued using the wrong VAT treatment. Any correction should be supported by accounting documentation and reviewed before VAT returns are finalized or amended.
Procurement and legal teams should consider adding VAT classification clauses to supply contracts involving medicines and medical devices. The contract should require suppliers to provide documentation when claiming VAT-exempt treatment and to notify the buyer if the FDA or BIR changes the product’s VAT status.
Finally, businesses should train billing and front-line accounting personnel. Many VAT errors arise not from legal interpretation but from system tagging and invoice preparation. The rule in RMC No. 19-2023 is simple but strict: the exemption for covered medicines and medical devices under the CREATE Act is tied to the FDA publication date of the updated list.
How Ablola, Saribong & Gueco Can Help
Ablola, Saribong & Gueco assists companies in reviewing VAT treatment, BIR compliance, tax audit exposure, invoicing practices, and documentation for VAT-exempt medicines, medical devices, and other regulated products. For healthcare businesses, importers, distributors, and corporate taxpayers, the correct VAT classification can affect pricing, contracts, tax returns, and audit risk.
If your business needs help confirming whether a medicine or medical device is VAT-exempt, correcting invoice treatment, preparing a BIR audit defense file, or aligning your accounting system with RMC No. 19-2023, our Makati-based tax and business law team can assist. Visit MakatiLawFirm.com to consult Ablola, Saribong & Gueco on BIR compliance and Philippine tax advisory matters.